Ma TKW, Kam KKH, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 2010;160(6):1273–92.

CAS  Article  Google Scholar 

Lumbers ER, Head | Richard, Smith GR, Delforce SJ, Jarrott B, Martin JH, et al. The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment. Pharmacol Res Perspect [Internet]. 2022;10:16. Available from: https://doi.org/10.1002/prp2.917.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):934–43.

CAS  Article  Google Scholar 

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020;395(10229):1054–62. Available from: https://doi.org/10.1016/S0140-6736(20)30566-3.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

CAS  Article  Google Scholar 

South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol [Internet]. 2020;16(6):305–7. Available from: https://doi.org/10.1038/s41581-020-0279-4.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med [Internet]. 2020;8(4):e21. Available from: https://doi.org/10.1016/S2213-2600(20)30116-8.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. UltraRapid Communication A Novel Angiotensin-Converting Enzyme – Related to Angiotensin 1–9. Circ Res. 2000;87:e1-9.

CAS  Article  Google Scholar 

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem [Internet]. 2000;275(43):33238–43. Available from: https://doi.org/10.1074/jbc.M002615200.

Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2/Angiotensin-(1–7)/Mas axis of the renin-angiotensin system: Focus on Angiotensin-(1–7). Physiol Rev. 2018;98(1):505–53.

CAS  Article  Google Scholar 

• Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):1–10. This comprehensive and very useful review describes the RAAS signalling pathways and the role of ACE2 enzyme in COVID19 infection.

Verma K, Pant M, Paliwal S, Dwivedi J, Sharma S. An insight on multicentric signaling of angiotensin II in cardiovascular system: A Recent Update. Front Pharmacol. 2021;12(August):1–18.

Google Scholar 

Theodorakopoulou MP, Alexandrou M-E, Boutou AK, Ferro CJ, Ortiz A, Sarafidis P. Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. Clin Kidney J. 2022;15(3):397–406.

CAS  Article  Google Scholar 

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.

CAS  Article  Google Scholar 

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8.

CAS  Article  Google Scholar 

Augustine R, Abhilash S, Nayeem A, Salam SA, Augustine P, Dan P, et al. Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation. Chem Biol Interact [Internet]. 2022;351(July 2021):109738. Available from: https://doi.org/10.1016/j.cbi.2021.109738.

Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun [Internet]. 2020;525(1):135–40. Available from: https://doi.org/10.1016/j.bbrc.2020.02.071.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80- ). 2020;367(6483):1260–3.

Baral R, Ali O, Brett I, Reinhold J, Vassiliou VS. COVID-19: A pan-organ pandemic. Oxford Med Case Reports. 2020;2020(12):423–9.

CAS  Article  Google Scholar 

Chou OHI, Zhou J, Lee TTL, Kot T, Lee S, Wai AKC, et al. Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clin Res Cardiol [Internet]. 2022;(0123456789):3–8. Available from: https://doi.org/10.1007/s00392-022-02007-0.

Zisman LS. ACE and ACE2: A tale of two enzymes. Eur Heart J. 2005;26(4):322–4.

CAS  Article  Google Scholar 

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10.

CAS  Article  Google Scholar 

Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and receptors. Kidney Int. 2005;68(5):2189–96.

CAS  Article  Google Scholar 

Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol - Ren Physiol. 2009;296(2):398–405.

Article  Google Scholar 

Tucker NR, Chaffin M, Bedi KC, Papangeli I, Akkad AD, Arduini A, et al. Myocyte-specific upregulation of ACE2 in cardiovascular disease: Implications for SARS-CoV-2-mediated myocarditis. Circulation. 2020;708–10.

Stegbauer J, Kraus M, Nordmeyer S, Kirchner M, Ziehm M, Dommisch H, et al. Proteomic analysis reveals upregulation of ACE2 (Angiotensin-Converting Enzyme 2), the Putative SARS-CoV-2 Receptor in Pressure-but Not Volume-Overloaded Human Hearts. Hypertension. 2020;2:E41–3.

Google Scholar 

•• Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–9. This experimental study was one of the first to prove that ACE2 is a crucial SARS-CoV receptor in vivo and delineates the mechanism by which acute lung failure is triggered during the acute viral illness.

Selçuk M, Çınar T, Keskin M, Çiçek V, Kılıç Ş, Kenan B, et al. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin Exp Hypertens [Internet]. 2020 Nov 16 [cited 2022 Apr 8];42(8):738–42. Available from: https://pubmed.ncbi.nlm.nih.gov/32569491/.

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.

CAS  Article  Google Scholar 

Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 Sep 1 [cited 2022 Apr 8];5(9):1020–6. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2770523.

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441–8.

CAS  Article  Google Scholar 

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431–40.

CAS  Article  Google Scholar 

Li M, Wang Y, Ndiwane N, Orner MB, Palacios N, Mittler B, et al. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. PLoS One [Internet]. 2021;16(3 March):1–16. Available from: https://doi.org/10.1371/journal.pone.0248652.

Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens. PLoS One [Internet]. 2020;15(6 June):1–10. Available from: https://doi.org/10.1371/journal.pone.0235248.

Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clin Exp Hypertens [Internet]. 2020;42(7):656–60. Available from: https://doi.org/10.1080/10641963.2020.1764018.

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;382(25): e102.

CAS  Article  Google Scholar 

•• Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. [cited 2022 Apr 6]. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. This position statement summarizes the strongest evidence available to date and emphasises the importance of continuing RAAS inhibitors when indicated for underlying conditions during the COVID19 pandemic.

Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician | American Heart Association [Internet]. [cited 2022 Apr 6]. Available from: https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician?utm_campaign=sciencenews19-20&utm_source=science-news&utm_medium=phd-link&utm_content=phd03-17-20.

EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic | European Medicines Agency [Internet]. [cited 2022 Apr 6]. Available from: https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic.

Lopes RD, S Macedo A V, M de Barros E Silva PG, Moll-Bernardes RJ, dos Santos TM, Mazza L, et al. Effect of discontinuing vs Continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19 a randomized clinical trial visual abstract supplemental content group information: A list of the BRACE CORONA Investigators appears in Supplement 2. JAMA [Internet]. 2021;325(3):254–64. Available from: https://jamanetwork.com/.

Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M, et al. Effects of renin–angiotensin–aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: a randomized triple-blind clinical trial. Am J Hypertens. 2021;34(November):1217–26.

CAS  Google Scholar 

Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med [Internet]. 2021 Mar 1 [cited 2022 Apr 8];9(3):275–84. Available from: http://www.thelancet.com/article/S2213260020305580/fulltext.

Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med [Internet]. 2021 Aug 1 [cited 2022 Apr 8];9(8):863–72. Available from: http://www.thelancet.com/article/S2213260021002149/fulltext.

Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, et al. Ramipril in high-risk patients with COVID-19. J Am Coll Cardiol [Internet]. 2020 Jul 21 [cited 2022 Apr 8];76(3):268–76. Available from: https://pubmed.ncbi.nlm.nih.gov/32470515/.

Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, et al. Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—a systematic review, meta-analysis, and meta-regression analysis. vol. 8, frontiers in medicine. Frontiers Media S.A.; 2022.

Baral R, White M, Vassiliou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 Patients. Curr Atheroscler Rep. 2020;22(10).

Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, et al. Comparative impacts of ACE (Angiotensin-Converting Enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension. 2020;E15–7.

Yan F, Huang F, Xu J, Yang P, Qin Y, Lv J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020;6(1).

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60.

CAS  Article  Google Scholar 

Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an italian cohort of 133 hypertensives. Am J Hypertens [Internet]. 2020 Oct 21 [cited 2022 Apr 7];33(10):944–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32511678/.

Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. Heart. 2020;106(19):1503–11.

Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, et al. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020;222(8):1256–64.

CAS  Article  Google Scholar 

•• Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):1–18. This systematic review and meta-analysis represents the largest to date and shows a potentially protective effect of the RAAS inihbitors in patients with COVID19 infection.

Duarte M, Pelorosso F, Nicolosi LN, Victoria Salgado M, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021;37.

Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine [Internet]. 2021;37:100957. Available from: https://doi.org/10.1016/j.eclinm.2021.100957.

Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Lauren, et al. Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury a randomized clinical trial key points + visual abstract + supplemental content. JAMA Netw Open [Internet]. 2022;5(3):222735. Available from: https://jamanetwork.com/.

Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):1–9.

Article  Google Scholar 

Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52(9):783–92.

CAS  Article  Google Scholar 

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905-913.e7.

CAS  Article  Google Scholar